CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for neurodegenerative diseases characterized by neuroinflam ...

CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of ...

At the recent AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Disease (PD), Cerevance announced that solengepras, a first-in-class G-protein coupled receptor 6 (GPR6) antagonist in ...

On 2 April, at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Disease, Cerevance announced that solengepras failed to meet its primary endpoint—change from baseline ...

Credit: Art_Photo via Shutterstock. On 2 April, at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Disease, Cerevance announced that solengepras failed to meet its primary ...

Image credit: Shutterstock / R Photography Background. US-based biotech Cerevance is continuing an ongoing pivotal study of its Parkinson’s disease candidate despite it showing no benefit compared to ...

UK-based clinical-stage biopharmaceutical company Cerevance has announced top-line results from the Phase II ASCEND trial of solengepras as an investigational monotherapy in patients with early, ...

Solengepras, the most advanced investigational treatment in Cerevance’s pipeline, is an oral, non-dopaminergic therapy in Phase 3 development for Parkinson’s disease. A brain-penetrant, specific ...

Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit a snag, with solengepras performing no better than placebo in phase 2 when given to people with early, untreated ...

Sleep deficiency was associated with atrophy of the inferior parietal region, which is observed in early Alzheimer's disease. (Journal of Clinical Sleep Medicine) Researchers assessed evidence ...

Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative, psychiatric, and central nervous system-controlled ...